We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Recipharm Increases Lyophilisation Capacity in Italy

Read time: Less than a minute

Recipharm has announced a €3.7 million investment to expand its lyophilisation capacity in Masate, Italy, in response to growing customer demand. The investment forms part of Recipharm’s strategy to become a leading lyophilisation provider, and is in addition to the ongoing investment at Recipharm in Wasserburg, Germany, where a further €32 million is currently being spent to increase capacity.

Specialising in aseptic manufacturing and filling of parenterals, Recipharm in Masate, located close to Milan, offers lyophilisation capabilities in both vials and ampoules. The investment will see the introduction of a new lyophiliser for vials, bringing the total number of machines from five to six
and increasing the facility’s capacity by approximately 20 per cent.

The new machine will allow the CDMO to support more drug developers with their stability
challenges and meet growing demand for its lyophilisation services, particularly in Europe, China
and Japan.

Commenting on the investment, General Manager Giorgio Bruno said: “We are experiencing
greater demand for lyophilisation capabilities from our customers, ranging from some of the largest pharmaceutical companies to small and mid-sized firms. As we continue to receive more requests from existing customers and new enquiries from drug developers in new territories, we needed to increase our capacity”.

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.